Abstract：Objective: To investigate carbohydrate antigen 125 (CA125),carbohydrate antigen 199 (CA199),human epididymisprotein 4 (HE4) and risk of ovarian malignancy algorith (ROMA) index for the prognosis of ovarian cancer. Methods: A retrospective analysis of 70 cases of ovarian cancer treated in our hospital from March 2017 to March 2019 was conducted,depending on the patient's survival,39 surviving patients were classified as the survival group,31 patients who died were classified as death group. The CA125,CA199,HE4 and ROMA indexes of the two groups of patients was recorded,and logistic regression analysis was applied to the impact of the above indexes on the prognosis of ovarian cancer,ROC curve analysis was applied to the predictive value of the above indexes on the prognosis of the disease. Results: The CA125,CA199,HE4 and ROMA indexes of the death group were significantly higher than those of the survival group,and there were statistical differences between the groups (P<0.05). Multivariate logistic regression analysis showed that CA125,CA199,HE4 and ROMA index were independent factors influencing the prognosis of ovarian cancer (P<0.05). ROC curve analysis showed that the area under the curve (Area Under Curve,AUC) of the CA125、CA199、HE4、ROMA index and four combinations for the prognosis of ovarian cancer was 0.758,0.874,0.800,0.833 and 0.887,respectively. The CA199 and four combinations had better predictive value for prognosis. Conclusion: CA125、CA199、HE4 and ROMA indices are independent prognostic risk factors for ovarian cancer. The level of the above indexes can predict the prognosis of the disease,the prediction value of the four combinations is the best,and the clinical can be used to predict the prognosis of the patients through the four combined tests.
周建平, 宋晓龙, 李玉芳, 杨茹, 马少君. CA125 CA199 HE4及ROMA指数对卵巢癌预后预测价值[J]. 河北医学, 2021, 27(3): 499-503.
ZHOU Jianping, SONG Xiaolong, LI Yufang, et al. The Predictive Value of CA125 CA199 HE4 and ROMA Index on the Prognosis of Ovarian Cancer. HeBei Med, 2021, 27(3): 499-503.
[1] 邢华蕊,冯亚妮,黎小芳,等.血清肿瘤标志物水平与卵巢癌患者病理特征及预后的关系分析[J].河北医学,2020,26(8):1404~1408. [2] 郑璐,刘晓岩,邵平.上皮性卵巢癌患者血清肿瘤标志物水平对临床疗效及预后价值的探讨[J].中国肿瘤临床与康复,2020,27(1):9~12. [3] Torre L A,Trabert B,Desantis C,et al.Ovarian cancer statistics,2018[J]. CA:A Cancer Journal for Clinicians,2018,68(4):284~296. [4] 傅志勤,鲁超,殷珂欣,等.HE4及CA125评估卵巢癌生物学行为及预后的临床研究[J].肿瘤学杂志,2019,25(3):239~242. [5] 张维维,张正伟,何朗.342例卵巢癌手术患者预后影响因素分析[J].中华肿瘤防治杂志,2019,26(17):1288~1295. [6] 朱耀东,张梅,李平.生存期超过3年卵巢癌患者临床特征及预后影响因素分析[J].实用临床医药杂志,2019,23(9):20~23. [7] 王灵芝,王健,张攀,等.MRI联合血清CA125、CA199对Ⅰ期上皮性卵巢癌的诊断价值[J].中国CT和MRI杂志,2019,17(2):57~59. [8] 党秋红,曹静,张欢欢,等.HE4在上皮性卵巢癌中的表达情况及其与临床特征及预后的关系分析[J].癌症进展,2018,16(5):629~631,635. [9] A R S,B X L,A Z W,et al.Circular RNAs and their emerging roles as diagnostic and prognostic biomarkers in ovarian cancer[J]. Cancer Letters,2020,4(73):139~147. [10] 龚剑锋,李秋红.AFP、ALP、CA125和HE4在卵巢癌诊断和预后评估中的价值探讨[J].标记免疫分析与临床,2018,25(7):1016~1020. [11] 王琴,苑文军,赵栋,等.HE4结合CA125预测卵巢癌治疗预后的价值[J].医学研究杂志,2019,48(2):43~47. [12] 李丹妍,王銮虹,邱小华,等.血清CA125、CA199、AFP和CEA联合检测在卵巢癌诊断中的临床价值[J].中国妇幼保健,2018,3(8):1731~1733. [13] 郭润梅,杜蓉,王丹,等.血清HE4、CA125浓度水平在预测上皮性卵巢癌预后中的价值[J].临床检验杂志,2019,37(2):117~120. [14] 万玲玲,李明,单武林,等.ROMA指数在绝经前女性卵巢癌诊断和疗效监测中的应用价值[J].临床输血与检验,2019,21(6):608~611.
2021, Vol. 27 
冀公网安备13080202000677号